Senior Biochemist
About the job
- A Master's degree in Biochemistry, Chemistry, or Biotechnology is required.
- Skills and working knowledge in high-performance liquid chromatography or ultra-performance liquid chromatography, ultraviolet-visible spectroscopy, gas chromatography, out-of-specification or out-of-trend handling, root cause analysis, and dissolution are required.
- Conduct analytical and microbiological testing of raw materials and finished pharmaceutical products for stability using high-performance liquid chromatography or ultra-performance liquid chromatography and potentiometry.
- Analyze product bioequivalency using next-generation sequencing, ultraviolet-visible spectroscopy, gas chromatography, Fourier-transform infrared spectroscopy, and thin-layer chromatography.
- Identify and develop analytical methods to compare dissolution profiles and processes for in-vivo bioequivalence studies using current good manufacturing practices, current good laboratory practices, Empower, a pH meter, dissolution equipment, and a Malvern Mastersizer 2000.
- Perform solubility studies of drug substances according to the Biopharmaceutics Classification System and FDA regulations.
- Coordinate and execute microbiological testing according to USP and USP-NF using out-of-specification or out-of-trend procedures and root cause analysis.
- Compile and analyze laboratory test data for physical, biochemical, chemical, and analytical testing of active pharmaceutical ingredients and pharmaceutical dosage forms using wet chemistry, high-performance liquid chromatography, gas chromatography, ion chromatography, differential scanning calorimetry, thermogravimetric analysis, an electron microscope, X-ray diffraction, particle-size analyzers, ultraviolet-visible spectroscopy, and Fourier-transform infrared spectroscopy.
- Interpret test results and established specifications and control limits to ensure data are appropriate for release.
About the company
Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
2014
Get referred to Granules
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 FY26 revenue rose 22% to INR 1,388 crores, led by North America and Europe.
- July 2026 inspections at Genome Valley and Chantilly improved regulatory optionality and capacity.
- Europe grew 151% year-on-year in FY26, while peptide CDMO opened a new revenue vertical.
What critics are saying
- FDA warning letter dated February 26, 2025 threatens Gagillapur product approvals until remediation closes.
- Reuters on April 9, 2026 reported record-keeping and contamination concerns still burden management.
- Any second FDA action at Gagillapur can shut U.S. launches and damage Granules' generics franchise.
What makes Granules unique
- Granules integrates APIs, PFIs, and dosages, preserving cost control across the value chain.
- February 2025 Senn Chemicals acquisition adds peptide CDMO capabilities and European regulated-market access.
- Granules shipped in 80 countries and won 94 approvals by August 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Flexible Work Hours